DYNE THERAPEUTICS INC. - COMMON STOCK

11,06

28-апреля-25 11:27:44

15 мин. задержка

Акции

-0,01

-0,05%

Сегодняшний диапазон

10,81 - 11,51

ISIN

N/A

Источник

NASDAQ

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

24 апр 2025 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

15 апр 2025 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 апр 2025 16:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

20 мар 2025 16:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

20 мар 2025 16:10:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

16 мар 2025 19:00:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

11 мар 2025 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

27 фев 2025 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

14 фев 2025 16:05:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

03 фев 2025 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

21 янв 2025 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

10 янв 2025 06:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

09 янв 2025 07:30:04 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

08 янв 2025 16:05:29 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences

07 ноя 2024 16:15:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

09 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

23 сен 2024 08:56:28 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Key Leadership Appointments

03 сен 2024 06:31:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

03 сен 2024 06:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.